Alnylam Pharmace. buy Needham & Company LLC
Summary
This prediction is currently active. With a performance of 53.64% the BUY prediction by Needham___Company_LL is a big success. This prediction currently runs until 09.10.24. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | -0.244% | -0.244% |
iShares Core DAX® | -1.471% | 1.895% |
iShares Nasdaq 100 | -0.486% | 4.395% |
iShares Nikkei 225® | -2.115% | 2.450% |
iShares S&P 500 | 0.394% | 3.118% |
Comments by Needham___Company_LL for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Needham___Company_LL for Alnylam Pharmace.
Alnylam Pharmace.
12.09.23
12.09.24
13.09.24
Alnylam Pharmace.
04.08.23
04.08.24
05.08.24